![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SFMBT1 |
Gene summary for SFMBT1 |
![]() |
Gene information | Species | Human | Gene symbol | SFMBT1 | Gene ID | 51460 |
Gene name | Scm like with four mbt domains 1 | |
Gene Alias | RU1 | |
Cytomap | 3p21.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R338 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51460 | SFMBT1 | HCC1_Meng | Human | Liver | HCC | 2.57e-22 | 1.30e-03 | 0.0246 |
51460 | SFMBT1 | HCC2 | Human | Liver | HCC | 7.19e-10 | 2.72e+00 | 0.5341 |
51460 | SFMBT1 | S014 | Human | Liver | HCC | 3.60e-11 | 5.30e-01 | 0.2254 |
51460 | SFMBT1 | S015 | Human | Liver | HCC | 8.00e-06 | 4.16e-01 | 0.2375 |
51460 | SFMBT1 | S016 | Human | Liver | HCC | 1.89e-09 | 4.66e-01 | 0.2243 |
51460 | SFMBT1 | S028 | Human | Liver | HCC | 1.14e-07 | 4.68e-01 | 0.2503 |
51460 | SFMBT1 | S029 | Human | Liver | HCC | 9.04e-05 | 3.88e-01 | 0.2581 |
51460 | SFMBT1 | HTA12-23-1 | Human | Pancreas | PDAC | 4.16e-05 | 6.36e-01 | 0.3405 |
51460 | SFMBT1 | HTA12-25-1 | Human | Pancreas | PDAC | 2.94e-04 | 4.86e-01 | 0.313 |
51460 | SFMBT1 | HTA12-26-1 | Human | Pancreas | PDAC | 1.49e-08 | 5.11e-01 | 0.3728 |
51460 | SFMBT1 | HTA12-29-1 | Human | Pancreas | PDAC | 7.93e-20 | 5.12e-01 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SFMBT1 | SNV | Missense_Mutation | novel | c.2257G>A | p.Asp753Asn | p.D753N | Q9UHJ3 | protein_coding | tolerated(0.19) | benign(0.051) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SFMBT1 | SNV | Missense_Mutation | c.840N>T | p.Lys280Asn | p.K280N | Q9UHJ3 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SFMBT1 | SNV | Missense_Mutation | c.1364N>A | p.Arg455Gln | p.R455Q | Q9UHJ3 | protein_coding | deleterious(0) | benign(0.271) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SFMBT1 | SNV | Missense_Mutation | c.224N>T | p.Thr75Ile | p.T75I | Q9UHJ3 | protein_coding | deleterious(0.01) | possibly_damaging(0.861) | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SFMBT1 | SNV | Missense_Mutation | c.1293T>G | p.Ser431Arg | p.S431R | Q9UHJ3 | protein_coding | deleterious(0.01) | benign(0.112) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SFMBT1 | SNV | Missense_Mutation | c.992N>C | p.Gly331Ala | p.G331A | Q9UHJ3 | protein_coding | tolerated(0.05) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
SFMBT1 | SNV | Missense_Mutation | c.1306N>C | p.Asp436His | p.D436H | Q9UHJ3 | protein_coding | deleterious(0.01) | probably_damaging(0.92) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SFMBT1 | SNV | Missense_Mutation | c.2509G>A | p.Glu837Lys | p.E837K | Q9UHJ3 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-E9-A1RE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
SFMBT1 | SNV | Missense_Mutation | novel | c.1240C>A | p.Leu414Met | p.L414M | Q9UHJ3 | protein_coding | tolerated(0.62) | possibly_damaging(0.462) | TCGA-GM-A2DN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
SFMBT1 | SNV | Missense_Mutation | novel | c.663N>T | p.Trp221Cys | p.W221C | Q9UHJ3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LD-A7W5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |